98%
921
2 minutes
20
Background: We hypothesized that the outcomes of trauma patients with a body mass index (BMI) equal to or greater than 30 compared to patients with BMI less than 30 would not differ at a level 1 trauma center that is also a Metabolic and Bariatric Surgery Center of Excellence in the Metabolic and Bariatric Surgery Accreditation Quality Improvement Program (MBSAQIP).
Study Design: Patients equal to and greater than 18 years old treated between 1/1/2018 and 12/31/2020 were included. Demographics, BMI, comorbidities, and outcomes (hospital-LOS, ICU-LOS, blood products used, and mortality) were compared between 2 groups: obese (BMI ≥30) vs non-obese (BMI <30).
Results: Of the 4192 patients identified, 3821 met the inclusion criteria; 3019 patients had a BMI <30, and 802 had a BMI ≥30. There was a statistically significant difference between the 2 groups with respect to gender (females: 57% vs 47%, < .0001) and age (median: 80 [IQR: 63-88] vs 69 [IQR: 55-81], < .0001). When adjusted for age, sex, DM, dementia, ISS, and ICU admission, there was no statistically significant difference in hospital-LOS (4.30 [95% CI: 4.10, 4.52] vs 4.48 [95% CI: 4.18, 4.79]) or mortality. No statistical differences were seen between the 2 groups in blood product use.
Conclusions: Obesity did not correlate with poorer outcomes at an ACS-verified level 1 Trauma Center and Bariatric Surgery Center of Excellence. Further studies are needed to determine whether outcomes vary at hospitals without both designations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/00031348221083954 | DOI Listing |
Rev Med Liege
September 2025
Service de Gastroentérologie, CHU Liège, Belgique.
Bariatric endoscopy is an increasingly recognized alternative to surgery for obesity treatment. Recent guidelines from leading medical societies (IFSO, ASMBS, ASGE, ESGE) have included endoscopic sleeve gastroplasty (ESG) and the intragastric balloon (IGB) in their recommendations. These procedures are indicated for patients with a body mass index (BMI) between 27 and 40 kg/m² who cannot or do not wish to undergo surgery.
View Article and Find Full Text PDFObesity (Silver Spring)
September 2025
Division of Diabetes and Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Objective: Vertical sleeve gastrectomy (VSG) promotes significant metabolic improvements, though the underlying molecular mechanisms are not fully understood. Emerging evidence suggests that small extracellular vesicles (sEVs) contribute to metabolic improvements post VSG, such as improved fatty liver disease or adipose tissue function; however, it is unclear how different organ-specific sEVs interact with various metabolic parameters. The objective of this study is to establish the role of organ-specific sEVs in the metabolic improvements post VSG.
View Article and Find Full Text PDFObes Surg
September 2025
Clinique Mutualiste de Pessac, Pessac, France.
Background: Preoperative treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) before bariatric surgery has not been studied. Therefore, we investigated the impact of neoadjuvant treatment with GLP-1 RAs on weight loss and postoperative outcomes in patients who underwent sleeve gastrectomy for severe obesity.
Method: A retrospective single-center study was conducted between January 2022 and December 2023.
Obes Surg
September 2025
E-Da Hospital, Kaohsiung City, Taiwan.
Background: We retrospectively evaluated the efficacy of using additional obesity management medications (OMMs) within the first year after undergoing laparoscopic sleeve gastrectomy (LSG).
Methods: We retrospectively analyzed 246 patients who underwent primary LSG in our institution and were followed up for at least 12 months. We collected body weights preoperatively and at three, six, 12, and 24 months postoperatively, along with body composition and laboratory results preoperatively and at 12 months.
Obes Surg
September 2025
Department of Experimental Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Background: Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are common bariatric procedures that lead to substantial and sustained weight loss. Although both procedures induce hormonal and physiological effects, RYGB includes both a restrictive and malabsorptive component due to anatomical rerouting, whereas SG is considered primarily restrictive. This study aimed to quantify differences in energy and fat absorption between both procedures using near-infrared spectroscopy (NIRS).
View Article and Find Full Text PDF